China-based Digital Precision Medicine (DPM), a molecular imaging and fluorescence endoscopy manufacturer, has reportedly raised hundreds of millions of renminbi in a Series B financing round. The round was co-led by Softbank China Venture Capital and Longmen Fund, with participation from Hangzhou Risheng Private Equity Fund Management Co., Ltd and Jiangsu Haoyue Private Equity Fund Management Co., Ltd. Proceeds will fund product innovation, market expansion, and team building.
Company Background
DPM, incubated by the Chinese Academy of Sciences’ Institute of Automation molecular imaging lab, offers advanced medical imaging solutions, including 4K fluorescence endoscope cameras, medical endoscope cold light sources, near-infrared fluorescence imaging systems, and fluorescence molecular imagers. The firm has 13 products with CE marks and National Medical Products Administration (NMPA) approvals.
Product Portfolio
DPM’s offerings also include fluorescence molecular imaging contrast agents and magnetic nanoparticle imaging inspection equipment. The company’s products aim to enhance diagnostic accuracy and procedural efficiency in fluorescence endoscopy and molecular imaging.-Fineline Info & Tech
